Department of Neurology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350001, Fujian, People's Republic of China.
Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350001, Fujian, People's Republic of China.
Acta Neurochir (Wien). 2019 Sep;161(9):1783-1791. doi: 10.1007/s00701-019-04006-z. Epub 2019 Jul 17.
High-sensitivity C-reactive protein (hs-CRP) is a well-recognized biomarker of neurologic complications and clinical outcome of stroke patients. However, whether hs-CRP can predict the occurrence of acute kidney injury (AKI) in aneurysmal subarachnoid hemorrhage (aSAH) patients is still unclear. The objective of this study was to assess the feasibility of using serum hs-CRP level to predict the occurrence of AKI in aSAH patients.
One hundred sixty-four aSAH patients were enrolled into a prospective observational study. AKI was diagnosed using the modified Kidney Disease Improving Global Outcomes (KDIGO) standard. The relationship between serum hs-CRP level at admission and occurrence of AKI was analyzed.
AKI occurred in 17 patients (10.4%) in this cohort. Patients with AKI had significantly higher hs-CRP levels than those without. The mortality of the AKI group tends to be higher than that of the non-AKI group, but the difference was not statistically significant (4/17 (23.5%) vs. 13/147 (8.8%), P = 0.081). After adjusting for possible confounding factors including World Federation of Neurosurgical Societies grade, diabetes, and serum creatinine, multivariate analysis revealed that serum hs-CRP level and antibiotic therapy were both significant factors independently associated with AKI following aSAH (serum hs-CRP: OR = 1.2, 95% confidence interval (CI) = 1.1-1.3, P = 0.003; antibiotic therapy: OR = 5.8, 95%CI = 1.6-20.7, P = 0.007). Receiver operating characteristic curve analysis showed that hs-CRP had a sensitivity of 76.5% and a specificity of 64.6% for predicting the development of AKI on the basis of the best thresholds. The post hoc log-rank test revealed that patients having serum hs-CRP level > 6.6 mg/L had a significantly higher AKI rate than patients having serum hs-CRP level ≤ 6.6 mg/L (P = 0.001).
Serum hs-CRP level might be helpful as a predictor for the development of AKI in aSAH patients. Delayed cerebral ischemia occurrence rate and mortality of patients with AKI tend to be higher than those of patients without in this cohort; however, they were not significantly different.
高敏 C 反应蛋白(hs-CRP)是公认的神经并发症和卒中患者临床结局的生物标志物。然而,hs-CRP 是否能预测颅内动脉瘤性蛛网膜下腔出血(aSAH)患者急性肾损伤(AKI)的发生尚不清楚。本研究旨在评估血清 hs-CRP 水平预测 aSAH 患者 AKI 发生的可行性。
164 例 aSAH 患者被纳入前瞻性观察研究。采用改良肾脏病改善全球结局(KDIGO)标准诊断 AKI。分析入院时血清 hs-CRP 水平与 AKI 发生的关系。
该队列中 17 例(10.4%)发生 AKI。AKI 组 hs-CRP 水平明显高于非 AKI 组。AKI 组的死亡率有高于非 AKI 组的趋势,但差异无统计学意义(4/17(23.5%)vs. 13/147(8.8%),P=0.081)。校正包括世界神经外科学会分级、糖尿病和血清肌酐在内的可能混杂因素后,多因素分析显示,血清 hs-CRP 水平和抗生素治疗均为 aSAH 后 AKI 的独立相关因素(血清 hs-CRP:OR=1.2,95%置信区间(CI)1.1-1.3,P=0.003;抗生素治疗:OR=5.8,95%CI 1.6-20.7,P=0.007)。受试者工作特征曲线分析显示,基于最佳阈值,hs-CRP 预测 AKI 发展的敏感度为 76.5%,特异度为 64.6%。事后对数秩检验显示,hs-CRP 水平>6.6mg/L 的患者 AKI 发生率明显高于 hs-CRP 水平≤6.6mg/L 的患者(P=0.001)。
血清 hs-CRP 水平可能有助于预测 aSAH 患者 AKI 的发生。本队列中,AKI 患者迟发性脑缺血发生率和死亡率有高于非 AKI 患者的趋势,但差异无统计学意义。